Skip to main content
Journal ArticleOPEN ACCESS

Breaking Down the Evidence for Bevacizumab in Ovarian Cancer

  • Shu C
  • Konner J
The Oncologist (2015) 20(2) 91-93
DOI: 10.1634/theoncologist.2014-0302
3Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bevacizumab has been FDA-approved for use in combination with single-agent chemotherapy for platinum-resistant ovarian cancer; however, its optimal role remains unclear. In this editorial, the timing, efficacy, safety, and rationale for use of bevacizumab in ovarian cancer are discussed.

Cite

CITATION STYLE

APA

Shu, C. A., & Konner, J. A. (2015). Breaking Down the Evidence for Bevacizumab in Ovarian Cancer. The Oncologist, 20(2), 91–93. https://doi.org/10.1634/theoncologist.2014-0302

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free